Federal Register / Vol. 89, No. 19 / Monday, January 29, 2024 / Notices 5547 

EXHIBIT 1—ESTIMATED BURDEN HOURS OVER 3 YEARS—Continued 

Type of information collection Number of 

respondents 

Number of 

responses per 

respondent 

Hours per 

response 

Total burden 

hours 

Telephone ........................................................................................................ 600 1 40/60 400 

Web-based ....................................................................................................... 3,000 1 10/60 500 

Focus Groups .................................................................................................. 1,500 1 2.0 3,000

In-person .......................................................................................................... 600 1 1.0 600 

Automated ** .................................................................................................... 1,500 1 1.0 1,500 

Cognitive Testing *** ........................................................................................ 600 1 1.5 900 

Totals ........................................................................................................ 13,800 na na 8,900 

* May include telephone non-response follow-up in which case the burden will not change. 

** May include testing of database software, CAPI software or other automated technologies. 

*** May include cognitive interviews for questionnaire or toolkit development, or ‘‘think aloud’’ testing of prototype websites.

EXHIBIT 2—ESTIMATED COST BURDEN OVER 3 YEARS

Type of information collection Number of 

respondents 

Total burden 

hours 

Average 

hourly 

wage rate * 

Total cost 

burden 

Mail/email ......................................................................................................... 6,000 2,000 $46.52 $93,040 

Telephone ........................................................................................................ 600 400 46.52 18,608 

Web-based ....................................................................................................... 3,000 500 46.52 23,260 

Focus Groups .................................................................................................. 1,500 3,000 46.52 139,560 

In-person .......................................................................................................... 600 600 46.52 27,912 

Automated ........................................................................................................ 1,500 1,500 46.52 69,780 

Cognitive Testing ............................................................................................. 600 900 46.52 41,868 

Totals ........................................................................................................ 13,800 8,900 na 412,028 

* Bureau of Labor & Statistics on ‘‘Occupational Employment and Wages, May 2022’’ found at the following URL https://www.bls.gov/oes/current/oes_nat.htm#29-0000 for the respondents. 

Request for Comments 

In accordance with the Paperwork 

Reduction Act, 44 U.S.C. 3501–3520, 

comments on AHRQ’s information 

collection are requested with regard to 

any of the following: (a) whether the 

proposed collection of information is 

necessary for the proper performance of 

AHRQ’s health care research and health 

care information dissemination 

functions, including whether the 

information will have practical utility; 

(b) the accuracy of AHRQ’s estimate of 

burden (including hours and costs) of 

the proposed collection(s) of 

information; (c) ways to enhance the 

quality, utility and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information upon the 

respondents, including the use of 

automated collection techniques or 

other forms of information technology. 

Comments submitted in response to 

this notice will be summarized and 

included in the Agency’s subsequent 

request for OMB approval of the 

proposed information collection. All 

comments will become a matter of 

public record. 

Dated: January 18, 2024. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2024–01610 Filed 1–26–24; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Reorganization of the Office of 

Strategic Business Initiatives 

AGENCY: Centers for Disease Control and 

Prevention (CDC), the Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: CDC has modified its 

structure. This notice announces the 

reorganization of the Office of Strategic 

Business Initiatives (SBI) to transfer its 

management of the CDC Gift Review 

Panel to the Office of Policy, 

Performance, and Evaluation. 

DATES: This reorganization was 

approved by the Director of CDC on 

January 17, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Kimberly Thurmond, Office of the Chief 

Operating Officer, Office of the Director, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

TW–2, Atlanta, GA 30329. Telephone 

770–488–4401; Email: reorgs@cdc.gov. 

SUPPLEMENTARY INFORMATION: Part C 

(Centers for Disease Control and 

Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 88 FR 69188–69190, 

dated October 5, 2023) is amended to 

reflect the reorganization of the Office of 

Strategic Business Initiatives within the 

Office of the Chief Operating Officer, 

Centers for Disease Control and 

Prevention. Specifically, the changes are 

as follows: 

I. Under Part C, Section C–B, 

Organization and Functions 

• Change all instances of the acronym 

SBI to OSBI. 

• Delete item (2) of the OSBI (CAJT) 

functional statement and insert the 

following: (2) strengthens CDC’s 

administrative guidance and change 

management through agency-wide 

conference, policy, delegations of 

authority, organization and functions, 

and records management. 


ddrumheller on DSK120RN23PROD with NOTICES1
5548 Federal Register / Vol. 89, No. 19 / Monday, January 29, 2024 / Notices 

• Delete item (5) of the Office of 

Business Integrity and Strategic 

Management (CAJTB) functional 

statement and renumber the remaining 

items accordingly. 

Delegations of Authority 

All delegations and redelegations of 

authority made to officials and 

employees of affected organizational 

components will continue in them or 

their successors pending further 

redelegation, provided they are 

consistent with this reorganization. 

(Authority: 44 U.S.C. 3101) 

Dia Taylor, 

Acting Chief Operating Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–01708 Filed 1–26–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifiers: CMS–10858, CMS– 

10215 and CMS–10394] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), Federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

the necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions, 

the accuracy of the estimated burden, 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected, and the use of automated 

collection techniques or other forms of 

information technology to minimize the 

information collection burden. 

DATES: Comments must be received by 

March 29, 2024. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: CMS, Office of Strategic 

Operations and Regulatory Affairs, 

Division of Regulations Development, 

Attention: Document Identifier/OMB 

Control Number: ll, Room C4–26–05, 

7500 Security Boulevard, Baltimore, 

Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, please access the CMS PRA 

website by copying and pasting the 

following web address into your web 

browser: https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/ 

PaperworkReductionActof1995/PRAListing. 

FOR FURTHER INFORMATION CONTACT: 

William N. Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 

and associated materials (see 

ADDRESSES). 

CMS–10858 Rebate Reduction 

Requests under Sections 11101 and 

11102 of the Inflation Reduction 

Act 

CMS–10215 Identifying Medicaid 

Payment for Physician 

Administered Drugs 

CMS–10394 Application To Be a 

Qualified Entity to Receive 

Medicare Data for Performance 

Measurement/Reapplication/ 

Annual Report Worksheet 

Under the PRA (44 U.S.C. 3501– 

3520), Federal agencies must obtain 

approval from the Office of Management 

and Budget (OMB) for each collection of 

information they conduct or sponsor. 

The term ‘‘collection of information’’ is 

defined in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA 

requires Federal agencies to publish a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, before 

submitting the collection to OMB for 

approval. To comply with this 

requirement, CMS is publishing this 

notice. 

Information Collection 

1. Type of Information Collection 

Request: New collection (Request for a 

new OMB control number); Title of 

Information Collection: Rebate 

Reduction Requests under Sections 

11101 and 11102 of the Inflation 

Reduction Act; Use: Under the authority 

in sections 11101 and 11102 of the 

Inflation Reduction Act of 2022 (Pub. L. 

117–169), the Centers for Medicare & 

Medicaid Services (CMS) is 

implementing the Medicare Part B Drug 

Inflation Rebate Program and the 

Medicare Part D Drug Inflation Rebate 

Program codified in section 1847A(i) 

and section 1860D–14B of the Social 

Security Act (‘‘the Act’’), respectively. 

In accordance with section 1847A(i) of 

the Act, for calendar quarters beginning 

January 1, 2023, a manufacturer of a Part 

B rebatable drug will owe a rebate, to be 

deposited in the Federal Supplementary 

Medical Insurance Trust Fund, if the 

amount specified in section 

1847A(i)(3)(A)(ii)(I) of the Act exceeds 

the inflation-adjusted payment amount, 

which is calculated as set forth in 

section 1847A(i)(3)(C) of the Act. A 

‘‘Part B rebatable drug’’ means a singlesource drug or biological product (as 

defined section 1847A(c)(6)(D) of the 

Act), including a biosimilar biological 

product (as defined section 

1847A(c)(6)(H) of the Act) but excluding 

a qualifying biosimilar biological 

product (as defined section 

1847A(b)(8)(B)(iii) of the Act), for which 

payment is made under Medicare Part 

B, except such term shall not include 

such a drug or biological product if, as 

determined by the Secretary, the average 

total allowed charges for such drug or 

biological product under Part B for a 

year per individual that uses such a 

drug or biological product are less than 

the applicable threshold; or that is a 

vaccine described in subparagraph (A) 

or (B) of section 1861(s)(10) of the Act. 

In accordance with Section 1860D–14B 

of the Act, for each 12-month applicable 

period, starting with the applicable 

period beginning October 1, 2022, a 

manufacturer of a Part D rebatable drug 

will owe a rebate, to be deposited in the 

Federal Supplementary Medical 

Insurance Trust Fund, if the annual 


ddrumheller on DSK120RN23PROD with NOTICES1